PMID- 25879426
OWN - NLM
STAT- MEDLINE
DCOM- 20160412
LR  - 20161125
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 33
IP  - 4
DP  - 2015 Aug
TI  - Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of 
      choice?
PG  - 227-35
LID - 10.1111/1755-5922.12124 [doi]
AB  - For decades, unfractionated heparin (UFH) has been widely used in catheterization 
      laboratories for anticoagulation for percutaneous coronary intervention (PCI). 
      The direct thrombin inhibitors, bivalirudin, has emerged as an alternative to UFH 
      for PCI procedures, due to its lower bleeding risk. More recently, randomized 
      trials and meta-analyses questioned the efficacy of bivalirudin, and demonstrated 
      that bivalirudin might be associated with a higher incidence of ischemic events 
      and in particular stent thrombosis. In this review, we discuss the pharmacology 
      of bivalirudin along with the clinical evidence comparing bivalirudin versus UFH 
      in patients undergoing PCI for various indications.
CI  - (c) 2015 John Wiley & Sons Ltd.
FAU - Mahmoud, Ahmed
AU  - Mahmoud A
AD  - Department of Medicine, University of Florida, Gainesville, FL, USA.
FAU - Saad, Marwan
AU  - Saad M
AD  - Department of Medicine, Seton Hall University School of Health and Medical 
      Sciences, Trinitas Regional Medical Center, Elizabeth, NJ, USA.
FAU - Elgendy, Akram Y
AU  - Elgendy AY
AUID- ORCID: 0000-0001-9853-7591
AD  - Department of Medicine, University of Florida, Gainesville, FL, USA.
FAU - Abuzaid, Ahmed
AU  - Abuzaid A
AD  - Department of Medicine, Creighton University, Omaha, NE, USA.
FAU - Elgendy, Islam Y
AU  - Elgendy IY
AD  - Department of Medicine, University of Florida, Gainesville, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Anticoagulants)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Acute Coronary Syndrome/blood/diagnosis/economics/mortality/*therapy
MH  - Animals
MH  - Anticoagulants/adverse effects/economics/*therapeutic use
MH  - Coronary Thrombosis/etiology
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Hemorrhage/chemically induced
MH  - Heparin/therapeutic use
MH  - Hirudins/adverse effects/economics
MH  - Humans
MH  - Myocardial Infarction/blood/diagnosis/economics/mortality/*therapy
MH  - Peptide Fragments/adverse effects/economics/*therapeutic use
MH  - *Percutaneous Coronary Intervention/adverse effects/economics/mortality
MH  - Recombinant Proteins/adverse effects/economics/therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Bivalirudin
OT  - Percutaneous coronary intervention
OT  - Revascularization
EDAT- 2015/04/17 06:00
MHDA- 2016/04/14 06:00
CRDT- 2015/04/17 06:00
PHST- 2015/04/17 06:00 [entrez]
PHST- 2015/04/17 06:00 [pubmed]
PHST- 2016/04/14 06:00 [medline]
AID - 10.1111/1755-5922.12124 [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2015 Aug;33(4):227-35. doi: 10.1111/1755-5922.12124.